Induced Pluripotent Cells for Blood Diseases

诱导多能细胞治疗血液疾病

• 批准号: 7672891
• 负责人: LEONARD Ira ZON
• 金额: $ 4.23万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7672891
• 关键词: Affect; Anemia; Animal Disease Models; Animal Model; Biological Assay; Biology; Blood; Bypass; Cell Line; Cells; Cellular Morphology; Chemicals; Childhood; Communities; Databases; Defect; Derivation procedure; Development; Diamond; Diamond-Blackfan anemia; Disease; Disease model; Down Syndrome; Evaluation; Fanconi' s Anemia; Fibroblasts; Foundations; Functional disorder; Genes; Genetic; Genetic Screening; Hematological Disease; Hematology; Hematopoiesis; Hematopoietic; Hereditary Disease; Human; Immunodeficient Mouse; In Vitro; Lead; Modeling; Morbidity - disease rate; Mutant Strains Mice; Pathogenesis; Pathway interactions; Patients; Phenotype; Procedures; Protocols documentation; Retroviridae; Screening procedure; Subfamily lentivirinae; Syndrome; System; Teratoma; Therapeutic; Transplantation; Work; base; body system; c-myc Genes; cell type; disease phenotype; high throughput screening; human disease; mortality; novel; novel therapeutics; pluripotency; progenitor; small hairpin RNA; small molecule; therapeutic target

DESCRIPTION (provided by applicant): The evaluation of patients with rare blood disorders has uncovered fundamental aspects of biology, pathophysiology and therapies. The affected gene for several rare genetic diseases has been recently isolated, including Diamond Blackfan anemia, Shwachman Diamond syndrome, Fanconi's anemia. The derivation of animal models for these diseases has proven difficult, as the mouse mutant phenotype does approximate the human disease in many cases. Here we propose to develop human iPS induced pluripotent cell lines from patients with genetic blood diseases (including the disorders listed above and Down's Syndrome). We plan to obtain fibroblasts from patients with the diseases, and introduce Oct4, Sox2, Klf4 and c-myc as retroviruses or lentiviruses. iPS lines will be derived based on cell morphology and pluripotency marker expression. These iPS cell lines will be characterized for their ability for form teratomas. Furthermore, we plan to characterize the biology of the disease in vitro by differentiating the iPS cells to form hematopoietic cell types in colony assays as well as by transplanting the differentiated cells into immunodeficient mice. A database will be constructed to help track the cell lines, provide information on their characterization, and to aid distribution to the community. We then plan to develop a screening system to find small molecules or shRNAs that will rescue the disease phenotype in vitro. These chemicals or genes will help understand the biology of the disease, establishing the pathogenesis and ultimately finding new therapies. Furthermore, this work should pave the way for the use of iPS cells for the study of other organ systems.

描述（由申请人提供）：对罕见血液疾病患者的评估揭示了生物学、病理生理学和治疗的基本方面。最近分离出了几种罕见遗传病的受影响基因，包括戴蒙德·布莱克凡贫血、施瓦赫曼·戴蒙德综合征、范可尼贫血。事实证明，建立这些疾病的动物模型很困难，因为小鼠突变表型在许多情况下确实与人类疾病相似。在这里，我们建议从患有遗传性血液疾病（包括上面列出的疾病和唐氏综合症）的患者中开发人类 iPS 诱导的多能细胞系。我们计划从疾病患者身上获取成纤维细胞，并引入Oct4、Sox2、Klf4和c-myc作为逆转录病毒或慢病毒。 iPS 系将根据细胞形态和多能性标记表达而衍生。这些 iPS 细胞系将​​以其形成畸胎瘤的能力为特征。此外，我们计划通过在集落测定中分化 iPS 细胞形成造血细胞类型以及将分化的细胞移植到免疫缺陷小鼠体内来表征该疾病的体外生物学特征。将构建一个数据库来帮助跟踪细胞系，提供有关其特征的信息，并帮助向社区分发。然后，我们计划开发一个筛选系统来寻找能够在体外挽救疾病表型的小分子或shRNA。这些化学物质或基因将有助于了解疾病的生物学、确定发病机制并最终找到新的疗法。此外，这项工作应该为使用 iPS 细胞研究其他器官系统铺平道路。